WO2024002256 - ANTI-EGFR/MET ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/002256
Publication Date
04.01.2024
International Application No.
PCT/CN2023/103952
International Filing Date
29.06.2023
Title **
[English]
ANTI-EGFR/MET ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-EGFR/MET ET LEURS UTILISATIONS
Applicants **
DOMA BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
Unit 301
Building C29, 218 Xinghu Street, Suzhou Industrial Park
Suzhou, Jiangsu 215127, CN
Inventors
HAN, Yanfei
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
SHANG, Chengzhang
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
LIU, Baihong
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
YANG, Yi
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
SHEN, Yuelei
No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park
Daxing District, Beijing 102600, CN
Priority Data
PCT/CN2022/102231
29.06.2022
CN
PCT/CN2022/108838
29.07.2022
CN
PCT/CN2022/116678
02.09.2022
CN
PCT/CN2022/141416
23.12.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2612 | |
| EPO | Filing, Examination | 17192 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 672 | |
| USA | Filing, Examination | 12560 |
Total: 33631 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided are antigen-binding protein constructs (e.g., bispecific antibodies, antigen-binding fragments thereof, or ADCs), wherein the antigen-binding protein constructs specifically bind to two different antigens (e.g., EGFR and MET).[French]
L'invention concerne des constructions de protéine de liaison à l'antigène (par exemple, des anticorps bispécifiques, des fragments de liaison à l'antigène de ceux-ci, ou des ADC), les constructions de protéine de liaison à l'antigène se liant de manière spécifique à deux antigènes différents (par exemple, EGFR et MET).